Overview
- Adjusted EPS came in at $1.36 on revenue of $8.96 billion, ahead of LSEG consensus estimates of $1.31 and $8.87 billion.
- Cardiovascular sales rose 10.8% to $3.44 billion, driven by pulsed field ablation adoption for treating atrial fibrillation.
- Diabetes segment revenue increased 10.3% as the company continues the planned separation of the business.
- Management raised the lower end of its fiscal 2026 adjusted EPS forecast to $5.62 and lifted full‑year organic revenue growth guidance to about 5.5%.
- The outlook includes an estimated $185 million tariff impact, and CEO Geoff Martha cited robust procedure volumes across end markets.